Abstract
The aim was to evaluate the cost of capecitabine vs conventional combination chemotherapics such as 5-fluorouracil (5-FU) for the treatment of metastatic colorectal cancer (MCRC) in Italy. The study was a multicenter, retrospective longitudinal treatment-cost analysis. Patient solder than 18 years, diagnosis of MCRC and at least 3 completed cycles of chemotherapy with oral capecitabine or 5-FU also in association with other chemotherapic agents were enrolled. Direct healthcare resources attributable to MCRC treatment were quantified using 2007prices and tariffs. The analysis was conducted from the National Health Service perspective with a 6-month time horizon. A total of 231 patients affected by MCRC (55% males; mean age 63.7±10.31 yrs) were studied. Total direct costs per patient per month in capecitabine and 5-FU groups were €1,001.66 ± €434.93 and € 3,172.81 ± € 1,232.37 respectively (p<0.0001). Oral capecitabine therapy cost the health service less than intravenous therapies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
